Medications in Palliative Care
2026 Edition • PCF9 • UPMC • GMMMG • WHOMedications in the
Palliative Care Setting
A complete clinical reference & AI-ready prompt generator
Self-contained • Evidence-based • 2026 sources
Disclaimer: This e-book is for educational and reference purposes only. It is NOT a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional or specialist palliative care team before prescribing, adjusting, or administering any medication. Doses are illustrative and must be individualized based on patient factors, local guidelines, and latest product information.
Introduction & Core Principles (2026)
Palliative pharmacotherapy focuses on symptom relief, quality of life, and dignity. Key 2026 principles from PCF9, UPMC 2025, GMMMG 2025, and WHO 2025 Controlled Medicines Guidelines:
- Start low, go slow, titrate to effect: Especially in frail, elderly, or organ-impaired patients.
- Anticipatory prescribing: Provide “just-in-case” subcutaneous medications for the last days of life (pain, breathlessness, agitation, nausea, secretions).
- Route matters: Oral preferred when possible; switch to subcutaneous (SC) or continuous subcutaneous infusion (CSCI / syringe driver) when swallowing is impaired.
- Deprescribing & deprescribing opioids: Review regularly; use equianalgesic charts with 25–50% dose reduction on rotation.
- Access & safety: WHO 2025 emphasizes removing barriers to essential opioids while preventing misuse.
- Multimodal & non-pharmacological: Always combine with positioning, fan therapy, communication, spiritual care.
Sources: PCF9 (2025/2026 updates), UPMC Palliative Care Reference Guide 2025, GMMMG Palliative Care Guidelines 6th Edition (2025).
2. Pain Management
Assessment: Use PQRSTUV or PAINAD for non-verbal patients. Identify nociceptive vs neuropathic pain.
Non-opioid & Adjuvant Agents (UPMC 2025)
- Acetaminophen: 650 mg q4h (max 3–4 g/day; reduce in liver impairment)
- Gabapentin: 300 mg HS, titrate to 3600 mg/day (renal adjustment)
- Duloxetine: 30–60 mg daily (neuropathic pain / anxiety)
- Dexamethasone: 4–8 mg/day (short course for bone/nerve compression)
Opioid Principles (GMMMG 2025 / PCF9)
Morphine remains first-line oral/SC opioid. Start opioid-naïve: Morphine IR 5 mg 4-hourly (frail/elderly 2.5 mg). Breakthrough dose = 1/6 of 24-hour total. Laxatives mandatory.
Equianalgesic example (oral to oral): Morphine 30 mg ≈ Oxycodone 20 mg ≈ Hydromorphone 7.5 mg. Always reduce 25–50% when rotating.
3. Dyspnea / Breathlessness
First-line pharmacologic: Low-dose opioids reduce perception of breathlessness (not hypoxia).
- Opioid-naïve: Morphine MR 5 mg BD or IR 2.5 mg PRN
- Already on opioid: Use 25–100% of 4-hourly dose PRN
- Anxiety component: Lorazepam 0.5–1 mg SL or Midazolam 2.5 mg SC PRN
Non-drug: Fan, positioning, reassurance (GMMMG 2025).
4. Nausea & Vomiting
Choose antiemetic by likely cause (GMMMG / UPMC):
| Cause | First-line | Dose example |
|---|---|---|
| Chemical/metabolic | Haloperidol | 0.5–1.5 mg nocte + PRN |
| Gastric stasis | Metoclopramide | 10 mg TDS (avoid obstruction) |
| Vestibular/central | Cyclizine | 50 mg TDS |
| Broad spectrum / end-of-life | Levomepromazine | 6.25–25 mg nocte |
5. Delirium & Terminal Agitation
Treat reversible causes first. Pharmacologic (UPMC 2025 / GMMMG):
- Haloperidol 0.5–1.5 mg nocte + PRN (max 10 mg/24h)
- Levomepromazine 6.25–25 mg SC/PO for agitated terminal phase
- Midazolam 2.5–5 mg SC PRN for severe agitation
6. Respiratory Secretions (“Death Rattle”)
Antisecretory agents (start early):
- Glycopyrronium 200 mcg SC 4-hourly or 600–1200 mcg/24h CSCI
- Hyoscine butylbromide 20 mg SC 4-hourly
Positioning and explanation to family are essential.
7. Constipation & Opioid Side Effects
Prophylactic laxatives with opioids: Senna + docusate or macrogol. For refractory: Methylnaltrexone SC (specialist).
8. Anxiety, Depression & Other Symptoms
Short prognosis (<4 weeks): Lorazepam / Midazolam. Longer: Sertraline or mirtazapine.
9. Quick Medication Reference Tables (2026)
| Drug | Route / Starting Dose (opioid-naïve adult) | Common PRN / 24h max | Notes / 2026 considerations |
|---|---|---|---|
| Morphine | PO 5 mg 4hly / SC 2.5 mg | 1/6 of daily dose | First-line; renal caution |
| Oxycodone | PO 2.5–5 mg 4hly | 1/6 of daily dose | Alternative if morphine intolerance |
| Buprenorphine patch | 5–10 mcg/h (7-day) | — | Renal safe; highlighted in 2026 updates |
| Haloperidol | 0.5–1.5 mg nocte | 10 mg/24h | Delirium / nausea |
| Midazolam | 2.5 mg SC PRN | 30 mg/24h CSCI | Agitation / breathlessness anxiety |
| Glycopyrronium | 200 mcg SC | 1200 mcg/24h | Secretions |
10. Special Considerations
Prefer fentanyl / buprenorphine patches. Reduce morphine/oxycodone dose 25–50%. Seek specialist advice.
Compatibility charts in PCF9. Common combinations: morphine + midazolam + glycopyrronium + levomepromazine.
GMMMG 2025 provides clear SC conversion algorithms (oral morphine → SC = divide by 2).
National policies must ensure equitable access to controlled medicines for palliative care.
🚀 AI Prompt Generator for Palliative Medications
Generate ready-to-copy, evidence-based prompts for any LLM (Grok, GPT, Claude, etc.) using the latest 2026 guidelines.
Prompts are pre-loaded with references to PCF9, UPMC 2025, GMMMG 2025, and WHO 2025 for accurate, up-to-date responses.
References & 2026 Sources
- UPMC Palliative & Supportive Institute. Palliative Care Reference Guide 2025.
- Greater Manchester & Eastern Cheshire Strategic Clinical Networks. Palliative Care Pain & Symptom Control Guidelines, 6th Edition, April 2025.
- Palliative Care Formulary (PCF9), 9th Edition, Aug 2025 + ongoing 2026 monograph updates (Pharmaceutical Press).
- WHO. Balanced National Controlled Medicines Policies to Ensure Medical Access and Safety, October 2025.
- National Coalition for Hospice and Palliative Care. Clinical Practice Guidelines for Quality Palliative Care, 4th Ed (with 2026 5th Ed panel underway).
- Jersey Hospice Care / other regional 2025 symptom management guidelines.
This entire e-book was compiled from publicly available, credible, active 2025–2026 resources. All content is embedded for offline use.
